Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been shown in several randomized trials to improve cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM). However, evidence regarding their effectiveness in patients with end-stage kidney disease, particularly those receiving maintenance dialysis, remains limited. We aimed to compare the cardiovascular effectiveness of GLP-1RAs versus dipeptidyl peptidase-4 inhibitors (DPP-4is) among patients with T2DM undergoing maintenance dialysis.
We emulated a target trial using a Japanese administrative claims database provided by DeSC Healthcare, Inc., covering the period from April 2014 through March 2024. We included patients aged 20 years or older with T2DM receiving maintenance dialysis who met the eligibility criteria between April 2015 and March 2023. Two sustained treatment strategies were compared: initiation and continuation of GLP-1RA therapy for 3 years versus initiation and continuation of DPP-4i therapy for 3 years after dialysis initiation. The primary outcome was a composite of major adverse cardiovascular events (MACE), including acute myocardial infarction, stroke, and cardiovascular death. We estimated the observational analogue of the per-protocol effect of sustained GLP-1RA use on the 3-year risk of MACE compared with DPP-4i use, using pooled logistic regression with inverse probability weighting to adjust for confounding.
Among 4,793 eligible patients, 557 initiated GLP-1RAs and 4,236 initiated DPP-4is. The estimated 3-year risks of MACE were 28.0% (95% confidence interval [CI], 21.0% to 35.8%) for GLP-1RAs and 36.0% (95% CI, 33.8% to 39.1%) for DPP-4is, yielding a 3-year risk difference of −8.0% (95% CI, −15.7% to −0.2%) and a 3-year risk ratio of 0.78 (95% CI, 0.58 to 0.99).
It was estimated that, compared with DPP-4is, GLP-1RAs lowered the 3-year risk of MACE by 22%. However, the estimates were imprecise and should be confirmed in future randomized trials.
